All In Biotech

Drug Trial Radar · NCT03160833

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

A Phase I/II, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Feb 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

33

Actual

Start

May 23, 2017

Primary completion

Dec 31, 2019

Study completion Jun 30, 2020

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
May 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose escalation study consisting of two stages: Dose-escalation stage (stage 1): Patients will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD (quaque die) and start on the DLT (Dose Limited Toxicity) assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment; Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, PD (pharmacodynamics) profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D (recommended phase 2 dose) in approximately 10 patients with advanced solid tumor.

Conditions

  • Solid Tumor, Adult

Interventions

  • HMPL-453Drug

    oral administrative

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTs by the NCI CTCAE v4.03Time frame: Cycle 1 (DLT assessment window 28 days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing 307 Hospital

    Beijing, Beijing Municipality, China

  • Cancer center of SYSU

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.